Chromosomal and genetic abnormalities in myeloma

Clinical and Laboratory Haematology

Volumn 24, Issue 5, 2002, Pages 259-269

  Ho, P Joy ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Chromosomal translocation; Karyotype; MGUS; Myeloma; Oncogenesis

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; RAS PROTEIN;

CHROMOSOME 13Q; CHROMOSOME 14Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; GENE CONTROL; GENE DELETION; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; GENE TRANSLOCATION; GENETIC ANALYSIS; GENETIC DAMAGE; HUMAN; IMMUNOGLOBULIN GENE; KARYOTYPE; MOLECULAR GENETICS; MULTIPLE MYELOMA; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; DISEASE PROGRESSION; GENES, IMMUNOGLOBULIN; GENES, MYC; GENES, RAS; HUMANS; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN CONSTANT REGIONS; IMMUNOGLOBULIN HEAVY CHAINS; MONOSOMY; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PROGNOSIS; TRANSLOCATION, GENETIC;

EID: 0036399570     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2257.2002.00456.x     Document Type: Review

References (70)

1. Avet-Loiseau H., Daviet A., Brigaudeau C., Callet-Bauchu E., Terre C., Lafage-Pochitaloff M., Desangles F., Ramond S., Talmant P. & Bataille R. (2001a) Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood 97, 822-825.
2. Avet-Loiseau H., Daviet A., Sauner S., Bataille R. & Intergroupe Francophone, M. (2000) Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. British Journal of Haematology 111, 1116-1117.
3. Avet-Loiseau H., Facon T., Daviet A., Godon C., Rapp M., Harousseau J., Grosbois B. & Bataille R. (1999a) 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multi-step process for the oncogenesis of multiple myeloma. Cancer Research 59, 4546-4550.
4. Avet-Loiseau H., Gerson F., Magrangeas F., Minvielle S., Harousseau J.L., Bataille R. & Intergroupe Francophone, M. (2001b) Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 98, 3082-3086.
5. Avet-Loiseau H., Li J., Facon T., Brigaudeau C., Morineau N., Maloisel F., Rapp M., Talmant P., Trimoreau F., Jaccard A., Harousseau J. & Bataille R. (1998) High incidence of translocations t (11; 14) (q13;q32) and t (4; 14) (p16;q32) in patients with plasma cell malignancies. Cancer Research 58, 5640-5645.
6. Avet-Loiseau H., Li J.Y., Morineau N., Facon T., Brigaudeau C., Harousseau J.L., Grosbois B. & Bataille R. (1999b) Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome. Blood 94, 2583-2589.
7. Bakkus M.H., Van Riet I., Van Camp B. & Thielemans K. (1994) Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. British Journal of Haematology 87, 68-74.
8. Bednarek A.K., Laflin K.J., Daniel R.L., Liao Q., Hawkins K. & a. & Aldaz C.M. (2000) WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected by breast cancer. Cancer Research 60, 2140-2145.
9. Bergsagel P.L., Chesi M., Nardini E., Brents L.A., Kirby S.L. & Kuehl W.M. (1996) Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America 93, 13931-13936.
10. Bergsagel P.L. & Kuehl W.M. (2001) Chromosome translocations in multiple myeloma. Oncogene 20, 5611-5622.
11. Billadeau D., Jelinek D.F., Shah N., LeBien T.W. & Van Ness B. (1995) Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6. Cancer Research 55, 3640-3646.
12. Billadeau D., Van Ness B., Kimlinger T., Kyle R.A., Therneau T.M., Greipp P.R. & Witzig T.E. (1996) Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood 88, 289-296.
13. Chesi M., Bergsagel P.L., Brents L.A., Smith C.M., Gerhard D.S. & Kuehl W.M. (1996) Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 88, 674-681.
14. Chesi M., Bergsagel P.L., Shonukan O.O., Martelli M.L., Brents L.A., Chen T., Schrock E., Ried T. & Kuehl W.M. (1998a) Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 91, 4457-4463.
15. Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A., Kuehl M. & Bergsagel P.L. (2001) Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 97, 729-736.
16. Chesi M., Nardini E., Brents L.A., Schrock E., Ried T., Kuehl W.M. & Bergsagel P.L. (1997) Frequent translocation t (4; 14) (p16.3; q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genetics 16, 260-264.
17. Chesi M., Nardini E., Lim R.S.C., Smith K.D., Kuehl W.M. & Bergsagel P.L. (1998b) The t (4; 14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in Igh/MMSET hybrid transcripts. Blood 92, 3025-3034.
18. Cigudosa J.C., Rao P.H., Calasanz M.J., Odero M.D., Michaeli J., Jhanwar S.C. & Chaganti R.S.K. (1998) Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood 91, 3007-3010.
19. Corradini P., Boccadoro M., Voena C. & Pileri A. (1993) Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG) - and IgA-secreting multiple myelomas. Journal of Experimental Medicine 178, 1091-1096.
20. Cui X., De Vivo I., Slany R., Miyamoto A., Firestein R. & Cleary M.L. (1998) Association of SET domain and myotubularin-related proteins modulates growth control. [see comments]. Nature Genetics 18, 331-337.
21. Desikan R., Barlogie B., Sawyer J., Ayers D., Tricot G., Badros A., Zangari M., Munshi N.C., Anaissie E., Spoon D., Siegel D., Jagannath S., Vesole D., Epstein J., Shaughnessy J., Fassas A., Lim S., Roberson P. & Crowley J. (2000) Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 95, 4008-4010.
22. Drach J., Ackermann J., Fritz E., Kromer E., Schuster R., Gisslinger H., DeSantis M., Zojer N., Fiegl M., Roka S., Schuster J., Heinz R., Ludwig H. & Huber H. (1998) Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 92, 802-809.
23. Drach J., Angerler J., Schuster J., Rothermundt C., Thalhammer R., Haas O.A., Jager U., Fiegl M., Geissler K. & Ludwig H. (1995) Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 86, 3915-3921.
24. Facon T., Avet-Loiseau H., Guillerm G., Moreau P., Genevieve F., Zandecki M., Lai J.L., Leleu X., Jouet J.P., Bauters F., Harousseau J.L., Bataille R., Mary J.Y. & Intergroupe Francophone, M. (2001) Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97, 1566-1571.
25. Finelli P., Fabris S., Zagona S., Baldini L., Intini D., Nobili L., Lombardi L., Maiolo A.T. & Neri A. (1999) Detection of t (4; 14) (p16.3; q32) chromosomal translocation in multiple myeloma by double-color fluoescent in situ hybridization. Blood 94, 724-732.
26. Fonseca R., Oken M.M. & Greipp P.R. (2001) The t (4; 14) (p16.3; q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood 98, 1271-1272.
27. Fonseca R., Witzig T.E., Gertz M.A., Kyle R.A., Hoyer J.D., Jalal S.M. & Greipp P.R. (1998) Multiple myeloma and the translocation t (11; 14) (q13;q32): a report on 13 cases. British Journal of Haematology 101, 296-301.
28. Fracchiolla N.S., Luminari S., Baldini L., Lombardi L., Maiolo A.T. & Neri A. (1998) FGFR3 gene mutations associated with human skeletal disorders occur rarely in multiple myeloma. Blood 92, 2987-2989.
29. Hatzivassiliou G., Miller I., Takizawa J., Palanisamy N., Rao P.H., Iida S., Tagawa S., Taniwaki M., Russo J., Neri A., Cattoretti G., Clynes R., Mendelsohn C., Chaganti R.S. & Dalla-Favera R. (2001) IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity 14, 277-289.
30. Ho P.J., Brown R.D., Pelka G., Basten A., Gibson J. & Joshua D.E. (2001) Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival. Blood 97, 490-495.
31. Hoyer J.D., Hanson C.A., Fonseca R., Greipp P.R., Dewald G.W. & Kurtin P.J. (2000) The (11; 14) (q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. American Journal of Clinical Pathology 113, 831-837.
32. Iida S., Rao P.H., Butler M., Corradini P., Boccadoro M., Klein B., Ghaganti R.S.K. & Dalla-Favera R. (1997) Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nature Genetics 17, 226-230.
33. Intini D., Baldini L., Fabris S., Lombardi L., Ciceri G., Maiolo A.T. & Neri A. (2001) Analysis of FGFR3 gene mutations in multiple myeloma patients with t (4; 14). British Journal of Haematology 114, 362-364.
34. Janssen J.W.G., Vaandrager J.W., Heuser T., Jauch A., Kluin P.M., Geelen E., Bergsagel P.L., Kuehl W.M., Drexler H.G., Otsuki T., Bartram C.R. & Schuuring E. (2000) Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t (11; 14) (q13;q32). Blood 95, 2691-2698.
35. Kanai M., Goke M., Tsunekawa S. & Podolsky D.K. (1997) Signal transduction pathway of human fibroblast growth factor receptor 3. Identification of a novel 66-kDa phosphoprotein. Journal of Biological Chemistry 272, 6621-6628.
36. Kataoka K., Nishizawa M. & Kawai S. (1993) Structure-function analysis of the maf oncogene product, a member of the b-Zip protein family. Journal of Virology 67, 2133-2141.
37. Königsberg R., Zojer N., Ackermann J., Krömer E., Kittler H., Fritz E., Kaufmann H., Nösslinger T., Reidl L., Gisslinger H., Jäger U., Simonitsch I., Heinz R., Ludwig H., Huber H. & Drach J. (2000) Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. Journal of Clinical Oncology 18, 804-812.
38. Lai J.L., Zandecki M., Mary J.Y., Bernardi F., Izydorczyk V., Flactif M., Morel P., Jouet J.P., Bauters F. & Facon T. (1995) Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 85, 2490-2497.
39. Li Z., Zhu Y.Y., Plowright E.E., Bergsagel P.L., Chesi M., Patterson B., Hawley T.S., Hawley R.G. & Stewart A.K. (2001) The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood 97, 2413-2419.
40. Malgeri U., Baldini L., Perfetti V., Fabris S., Vignarelli M.C., Colombo G., Lotti V., Compasso S., Bogni S., Lombardi L., Maiolo A.T. & Neri A. (2000) Detection of t (4; 14) (p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Research 60, 4058-4061.
41. Mittrucker H.W., Matsuyama T., Grossman A., Kundig T.M., Potter J., Shahinian A., Wakeham A., Patterson B., Ohashi P.S. & Mak T.W. (1997) Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 275, 540-543.
42. Naski M.C., Wang Q., Xu J. & Ornitz D.M. (1996) Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nature Genetics 13, 233-237.
43. Neri A., Baldini L., Trecca D., Cro L., Polli E. & Maiolo A.T. (1993) p53 gene mutationsin multiple myeloma are associated with advanced forms of malignancy. Blood 81, 128-135.
44. Neri A., Murphy J.P., Cro L., Ferrero D., Tarella C., Baldini L. & Dalla-Favera R. (1989) Ras oncogene mutation in multiple myeloma. Journal of Experimental Medicine 170, 1715-1725.
45. Nishida K., Tamura A., Nakazawa N., Ueda Y., Abe T., Matsuda F., Kashima K. & Taniwaki M. (1997) The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 90, 526-534.
46. Perez-Castro A.V., Wilson J. & Altherr M.R. (1997) Genomic organization of the human fibroblast growth factor receptor 3 (FGFR3) gene and comparative sequence analysis with the mouse fgfr3 gene. Genomics 41, 10-16.
47. Plowright E.E., Li Z., Bergsagel P.L., Chesi M., Barber D.L., Branch D.R., Hawley R.G. & Stewert A.K. (2000) Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 95, 992-998.
48. Preudhomme C., Facon T., Zandecki M., Vanrumbeke M., Lai J.L., Nataf E., Loucheux-Lefebvre M.H., Kerckaert J.P. & Fenaux P. (1992) Rare occurrence of P53 gene mutations in multiple myeloma. British Journal of Haematology 81, 440-443.
49. Pruneri G., Fabris S., Baldini L., Carboni N., Zagano S., Colombi M.A., Ciceri G., Lombardi L., Rocchi M., Buffa R., Maiolo A.T. & Neri A. (2000) Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t (11; 14). American Journal of Pathology 156, 1505-1513.
50. Rao P.H., Cigudosa J.C., Ning Y., Calasanz M.J., Iida S., Tagawa S., Michaeli J., Klein B., Dalla-Favera R., Jhanwar S.C., Ried T. & Chaganti R.S.K. (1998) Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. Blood 92, 1743-1748.
51. Reiman T., Seeberger K., Taylor B.J., Szczepek A.J., Hanson J., Mant M.J., Coupland R.W., Belch A.R. & Pilarski L.M. (2001) Persistent preswitch clonotypic myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone. Blood 98, 2791-2799.
52. Richelda R., Ronchetti D., Baldini L., Cro L., Viggiano L., Marzella R., Rocchi M., Otsuki T., Lombardi L., Maiolo A.T. & Neri A. (1997) A novel chromosomal translocation t (4; 14) (p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 90, 4062-4070.
53. Sawyer J.R., Lukacs J.L., Munshi N., Desikan K.R., Singhal S., Mehta J., Siegel D., Shaughnessy J. & Barlogie B. (1998) Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood 92, 4269-4278.
54. Sawyer J.R., Lukacs J.L., Thomas E.L., Swanson C.M., Goosen L.S., Sammartino G., Gilliland J.C., Munshi N.C., Tricot G., Shaughnessy J.D. Jr & Barlogie B. (2001) Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. British Journal of Haematology 112, 167-174.
55. Sawyer J.R., Waldron J.A., Jagannath S. & Barlogie B. (1995) Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genetics and Cytogenetics 82, 41-49.
56. Schwarze M.M. & Hawley R.G. (1995) Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL. Cancer Research 55, 2262-2265.
57. Seong C., Delasalle K., Hayes K., Weber D., Dimopoulos M., Swantkowski J., Huh Y., Glassman A., Champlin R. & Alexanian R. (1998) Prognostic value of cytogenetics in multiple myeloma. British Journal of Haematology 101, 189-194.
58. Shaughnessy J., Gabrea A., Qi Y., Brents L., Zhan F., Tian E., Sawyer J., Barlogie B., Bergsagel P.L. & Kuehl M. (2001) Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 98, 217-223.
59. Sherr C.J. (2000) The Pezcoller lecture: cancer cell cycles revisited. Cancer Research 60, 3689-3695.
60. Shou Y., Martelli M.L., Gabrea A., Qi Y., Brents L.A., Roschke A., Dewald G., Kirsch I.R., Bergsagel P.L. & Kuehl W.M. (2000) Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America 97, 228-233.
61. Stec I., Wright T.J., van Ommen G.B., de Boer P.A.J., van Haeringen A., Moorman A.F.M., Altherr M.R. & den Dunnen J.T. (1998) WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t (4; 14) multiple myeloma. Human Molecular Genetics 7, 1071-1082.
62. Szczepek A.J., Seeberger K., Wizniak J., Mant M.J., Belch A.R. & Pilarski L.M. (1998) A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood 92, 2844-2855.
63. Taniwaki M., Nishida K., Takashima T., Nakagawa H., Fujii H., Tamaki T., Shimazaki C., Horiike S., Misawa S., Abe T. & Kashima K. (1994) Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. Blood 84, 2283-2290.
64. Taniwaki M., Nishida K., Ueda Y. & Takashima T. (1996) Nonrandom chromosomal rearrangements and their implications in clinical features and outcome of multiple myeloma and plasma cell leukemia. Leukemia and Lymphoma 21, 25-30.
65. Tricot G., Barlogie B., Jagannath S., Bracy D., Mattox S., Vesole D.H., Naucke S. & Sawyer J.R. (1995) Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86, 4250-4256.
66. Webster M.K., D'Avis P.Y., Robertson S.C. & Donoghue D.J. (1996) Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Molecular and Cellular Biology 16, 4081-4087.
67. Weh H.J., Bartl R., Seeger D., Selbach J., Kuse R. & Hossfeld D.K. (1995) Correlations between karyotype and cytologic findings in multiple myeloma. Leukemia 9, 2119-2122.
68. Yoshida S., Nakazawa N., Iida S., Hayami Y., Sato S., Wakita A., Shimizu S., Taniwaki M. & Ueda R. (1999) Detection of MUM1/IRF4-IgH fusion in multiple myeloma. Leukemia 13, 1812-1816.
69. Zandecki M., Facon T., Preudhomme C., Vanrumbeke M., Vachee A., Quesnel B., Lai J.L., Cosson A. & Fenaux P. (1995) The retinoblastoma gene (RB-1) status in multiple myeloma: a report on 35 cases. Leukemia and Lymphoma 18, 497-503.
70. Zojer N., Konigsberg R., Ackermann J., Fritz E., Dallinger S., Kromer E., Kaufmann H., Riedl L., Gisslinger H., Schreiber S., Heinz R., Ludwig H., Huber H. & Drach J. (2000) Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 95, 1925-1930.